Ranger Investment Management’s Amedisys AMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-198,476
Closed -$18.9M 95
2023
Q4
$18.9M Buy
198,476
+1,155
+0.6% +$108K 1.14% 45
2023
Q3
$18.4M Sell
197,321
-7,225
-4% -$668K 1.22% 39
2023
Q2
$18.7M Buy
204,546
+6,170
+3% +$506K 1.13% 39
2023
Q1
$14.6M Buy
198,376
+12,981
+7% +$1.12M 0.98% 39
2022
Q4
$15.5M Buy
185,395
+96,130
+108% +$8.67M 1.15% 36
2022
Q3
$8.64M Buy
89,265
+4,251
+5% +$507K 0.68% 47
2022
Q2
$8.94M Buy
+85,014
New +$10.9M 0.68% 47

Other funds holding AMED

Ranger Investment Management's AMED Position: Q1 2024 in Review

Ranger Investment Management sold out of Amedisys (AMED) in Q1 2024, closing a stake of 198,476 shares — an estimated $18.9M sold.

Ranger Investment Management first reported a position in AMED in Q2 2022 and held it in 7 quarters. The position peaked at $18.9M in Q4 2023. 284 funds tracked by Wall St. Rank hold AMED as of Q1 2024.

  • Ranger Investment Management reported no remaining Amedisys position as of Q1 2024 after selling out during the quarter.
  • Ranger Investment Management sold 198,476 Amedisys shares in Q1 2024, an estimated $18.9M.
  • Ranger Investment Management first reported a position in Amedisys in Q2 2022 and held it in 7 quarters.
  • Ranger Investment Management's Amedisys position peaked at $18.9M in Q4 2023.
  • 284 funds tracked by Wall St. Rank held Amedisys as of Q1 2024.

Based on Ranger Investment Management's 13F filing for Q1 2024, filed 15 May 2024.